Phase A — Understand the business
Lens 1 · Company Overview
KLA is the process-control layer of semiconductor manufacturing — the company that tells a fab whether the chips it is making are good. It sells defect-inspection systems, metrology (measurement) tools, in-situ process monitoring, computational-lithography software, and yield-analytics. Its tools are embedded at virtually every step of the wafer flow, repeatedly, to catch defects and drift before billions of dollars of wafers are scrapped.
The model has three structural features that make it unusually high-quality:
- It scales with complexity, not volume. Conventional fab equipment (deposition, etch, litho) scales with wafer starts. Inspection/metrology scales with the number of process steps that need checking — which multiplies as nodes shrink below 5nm and chips go 3D (stacking, chiplets, HBM, advanced packaging). So KLA's content-per-wafer rises every node even if unit volumes are flat.
- A large, sticky installed-base service annuity. Service was
22% of FY2025 revenue ($2.68B), with >80% of service revenue on multi-year contracts. This is the recurring, recession-dampening ballast under a cyclical-equipment top line.
- Mission-critical, low-substitutability position. A failed inspection tool doesn't slow a fab — it blinds it. That gives KLA pricing power and a seat at the leading-edge-roadmap table.
Segments (FY2025, fiscal year ended 2025-06-30): three reportable segments — Semiconductor Process Control ($10.95B), Specialty Semiconductor Process ($587M), PCB & Component Inspection (~$622M); total ~$12.16B.
Customers: the leading-edge foundry/logic and memory makers — TSMC, Samsung, Intel, SK Hynix, Micron — plus OSAT/advanced-packaging houses. Customer concentration is high and typical for WFE (a handful of leading-edge fabs drive the bulk of leading-edge tool demand); exact >10% customer disclosure n/a (would be in the 10-K customer-concentration note; upgrade on filing ingest). Suppliers: precision optics, lasers, e-beam columns, sensors — specialized but not single-source at the level KLA's own tools are to its customers. Competitors: Applied Materials (PDC group), Onto Innovation, Hitachi High-Tech, Camtek, plus ASML adjacency in computational litho/metrology.
Lens 2 · Supply Chain
KLA sits at the head of the semiconductor value chain — it is part of the equipment tier that all downstream silicon depends on:
Equipment (ASML · Applied Materials · Lam · KLA · Tokyo Electron) → Foundry (TSMC · Samsung · Intel) → Fabless (NVIDIA · AMD · Broadcom) → Advanced packaging (TSMC CoWoS · Amkor · ASE) → OEM/ODM → Hyperscaler (Microsoft · Meta · Google · Amazon).
KLA's specific position in that map:
- Upstream of KLA (its suppliers): precision-optics vendors (Zeiss-class optics for brightfield inspection), high-power laser and EUV-actinic light sources, e-beam/electron-optics columns, motion stages, and detector/sensor supply. These are specialized but multi-sourced; KLA is the system integrator. Named single-source exposures
n/a (10-K supplier note).
- KLA's customers (downstream): the leading-edge fabs. Demand is gated by the same chokepoints the KB tracks — CoWoS advanced packaging (severity 9/10, owned by TSMC, NVIDIA secures ~60% of capacity, ramping ~35K→75K→130K wafers/mo by late 2026) and HBM3E/HBM4 (severity 9/10, SK Hynix ~60% share). This is the key second-order read: every incremental CoWoS wafer and HBM stack adds inspection/metrology steps — KLA is a picks-and-shovels beneficiary of the AI packaging bottleneck, not a victim of it.
- The binding industry constraint is capacity, not demand. CEO Rick Wallace on the Q3 FY2026 call: "WFE is literally just as fast as we can go as an industry.". KLA's order book is gated by how fast the whole equipment industry can build leading-edge tools.
Chokepoint KLA itself controls: optical wafer inspection (>85% share) is effectively a single-source dependency for its customers — there is no second supplier of brightfield/e-beam inspection at KLA's sensitivity. That is the supply-chain power position.
Lens 3 · Competitive Advantages (moats)
KLA has one of the widest moats in all of semiconductors, arguably wider than ASML's because it spans more product categories:
- Share dominance → data flywheel. ~58% of the total process-control/metrology/inspection market; >85% in optical wafer inspection; metrology+inspection share rose 72.6% (2024) → 73.8% (2025) while #2 Applied Materials fell to ~9.8%. Every tool in the field feeds defect-signature data back into KLA's algorithms — a flywheel a sub-scale rival cannot replicate.
- Switching costs / requalification risk. Process-control recipes are co-developed with the fab and locked into the production line. Swapping inspection vendors means requalifying yield at the leading edge — enormous risk for a fab racing a node ramp. Customers don't switch; they expand.
- Multi-generation R&D head start + capital intensity. Inspection sensitivity must stay ahead of the smallest defect that matters at each node. KLA out-invests the field in process-control R&D; a challenger must fund years of catch-up with no installed base to amortize it.
- Bargaining power. KLA needs the leading-edge fabs and they need KLA — but at the leading edge the dependency is asymmetric in KLA's favor: there is no alternative inspection roadmap. That shows up as ~62% non-GAAP gross margin — best-in-class for capital equipment.
Process-control intensity is the moat's compounding engine. Process-control as a share of the WFE budget rose 5.3% (six years ago) → 7.4% (2025), and KLA's 2030 model targets 9% on a $215B equipment market. The moat doesn't just hold — its addressable slice of every fab dollar grows each node.
The one genuine vulnerability: geopolitics/China localization (see Lens 13), not a technology challenger.
Lens 4 · Segments (revenue by product & geography)
Segment figures from secondary reporting of the FY2025 10-K — label `` until upgraded by filing ingest. Note a reporting-taxonomy split: KLA reports 3 reportable segments, but also discloses a product-line view (Defect Inspection / Patterning / Service / etc.). Both are below.
By reportable segment (FY2025):
| Segment | FY2025 revenue | Share |
|---|
| Semiconductor Process Control | ~$10.95B | ~90% |
| Specialty Semiconductor Process | ~$587M | ~5% |
| PCB & Component Inspection | ~$622M | ~5% |
| Total | ~$12.16B | 100% |
By product line (FY2025):
| Product line | FY2025 revenue |
|---|
| Defect Inspection | ~$6.20B |
| Patterning | ~$2.20B |
| Service | ~$2.68B (~22% of total) |
| Specialty Semiconductor Process | ~$517M |
| PCB & Component Inspection | ~$356M |
| Other | ~$205M |
Trend / cause: Full-year revenue +17% YoY to $12.16B; Q4 FY2025 wafer-inspection/process-control revenue $1.772B, +52% YoY / +18% QoQ — accelerating, driven by leading-edge foundry/logic + HBM + advanced packaging. Advanced packaging is the standout growth vector: ~$635M (CY2025) → ~$1B (CY2026), +70% YoY, with KLA at the #1 process-control position in advanced wafer-level packaging.
By geography (FY2025): China $4.04B ≈ 33% of total (KLA's own disclosure framing puts the full-year China share dropping from 41% (FY2024) → ~30% as export controls bit). Recent quarterly mix: Taiwan ~30%, China ~26%, North America ~14%, with Korea rising to ~15%. The China de-risking is the dominant geographic story — see Lens 8 & 13.
Phase B — Measure performance
Lens 5 · Earnings Result (latest print — Q3 FY2026, quarter ended 2026-03-31, reported 2026-04-29)
[All figures web: KLA 8-K / Motley Fool & Investing.com transcripts, 2026-04-29 unless noted]
- Revenue $3.415B — up +4% QoQ / +11% YoY; beat the $3.36B consensus and the $3.35B guidance midpoint.
- Non-GAAP diluted EPS $9.40 (pre-split basis) — beat $9.15 consensus, ~45bps above guidance.
- Non-GAAP gross margin 62.2% — 45bps above guidance midpoint; driven by service mix + manufacturing scale on higher volume.
- Drivers: leading-edge foundry/logic + HBM; "AI is a core driver of KLA's performance." Foundry/logic ≈ 82% of semi-process-control systems revenue, memory ≈ 18%.
- Guidance raised: FY2026 total revenue growth to high-teens %; semi-process-control systems revenue to grow >20% in CY2026. Q4 FY2026 guide: revenue $3.575B ± $200M, GM 61.75% ±1pt, non-GAAP EPS $9.87 ± $1.
- Margin flags: ~100bps GM headwind from elevated DRAM ship costs (memory pricing), expected to persist through ≥CY2026; tariffs 50–100bps headwind, expected to moderate.
- Balance-sheet / capital return: new $7B buyback authorization; 17th consecutive annual dividend increase; targeting >90% of FCF returned. FY2025 context: GAAP net income ~$4.06B, FCF margin ~30.8%.
- Market reaction: the print was strong, but the stock's reaction was muted-to-negative into/after the event because expectations were already extreme (the stock had run +76.9% over 3 months pre-split, +195% over 1 year). The tell: at this valuation, beats are the baseline, not the catalyst.
Unusual vs. own history: revenue growth re-accelerated despite the China headwind — the AI/packaging/process-control-intensity engine is more than offsetting the structural China step-down. That is the bull thesis in one data point.
Lens 6 · Earnings Calls (sentiment trend)
No transcripts in the research layer — `` only, and a full multi-call sentiment series is n/a (only the Q3 FY2026 call was fetched in depth). What is sourced:
- Tone (Q3 FY2026): confident and supply-constrained, not demand-anxious. The defining quote — "WFE is literally just as fast as we can go as an industry" — reframes the bottleneck from "will demand come?" to "how fast can we ship?" That is the most bullish posture an equipment CEO can take.
- Recurring themes management leans on: AI as core driver; advanced packaging (#1 position, path to ~$1B); process-control intensity rising every node; service annuity (>80% multi-year).
- What they now front-foot vs. before: China is discussed as a managed step-down (de-risking to ~30% and reallocating to Korea/Taiwan), no longer a surprise overhang — a tonal shift from the 2024–25 export-control shock.
- Honest caveats they volunteer: DRAM-cost and tariff margin headwinds were quantified rather than buried — a credibility positive.
Open item for refresh: ingest the last 3–4 transcripts to build a real tone-trend series (the lens's core requirement). Currently a single-call read.
Lens 7 · Comps
| Company | Ticker | Mkt cap | Fwd P/E | EV/EBITDA | Div yld | ROE | Notes |
|---|
| KLA | KLAC | ~$333B | ~35 (trailing ~72 ) | ~34 | ~0.38% | very high (FY25 NI $4.06B on modest equity; precise 5-yr-avg ROE n/a) | ~58% process-control share |
| ASML | ASML | ~$654B | ~51 | ~52 | n/a | n/a | EUV monopoly; richest multiple |
| Applied Materials | AMAT | ~$282–360B | ~33–40 | ~29–42 | ~0.42% | ~40% | Broadest WFE; lowest multiple |
| Lam Research | LRCX | ~$471B | ~37 | ~33–46 | ~0.48% | ~67% | Etch/deposition leader |
Conflicts I will not paper over:
- AMAT market cap spans $282B (Feb-2026 datapoint) to ~$360B (a search-agg "higher than" framing) — likely a timing gap (Feb vs June) given the sector's run; treat ~$300–360B as the live range.
- EV/EBITDA for AMAT and LRCX vary widely by source (different EBITDA definitions / trailing-vs-NTM). Do not anchor a thesis on a single figure.
- Lam mkt cap (~$471B) > ASML "US-peer" framing sits oddly against ASML ~$654B — both can be true (ASML is the largest), but the relative ordering in some snippets is muddled; trust the absolute figures, not the comparative adjectives.
Read-through: KLA's forward P/E (~35) is mid-pack — cheaper than ASML (~51) and roughly in line with LRCX (~37) and AMAT (~33–40), despite the widest moat and highest gross margin in the group. That is the crux of the value debate: a best-in-class business at a sector-average multiple. The bear retort: trailing P/E (~72) and EV/EBITDA (~34) are absolutely high, and the "cheap on forward" rests on the high-teens-growth guide actually landing.
Lens 8 · Stock-Price Catalysts (what moves KLAC >5%)
Pattern over the last ~2 years:
- U.S.–China export controls = the dominant macro catalyst. Dec-2024: KLA guided a ~$500M / ~20% China-revenue hit for 2025 under new curbs → shares fell on export-control fallout. China share compressed 41%→30%. This is the single biggest swing factor in the name's recent history.
- Earnings beats + guidance raises repeatedly drove the stock — but increasingly the magnitude of the raise matters more than the beat, because beats are priced in. The +76.9%/3-month, +195%/1-year run into mid-2026 was an AI-capex/process-control-intensity re-rating, not a single print.
- Capital-return announcements ($7B buyback, 21% dividend hike, 10-for-1 split) drove discrete pops (one report: +5.6% on the buyback/dividend news; the pre-split run-up itself was +12% ahead of the split).
- The split mechanics caused a near-term air-pocket: −7.44% on 2026-06-16 to $237.33 post-split, part of a ~−7% split-week drawdown — mechanical/sentiment, not fundamental.
What the market actually reacts to for this name: (1) China policy headlines, (2) the trajectory of the AI-capex / WFE / process-control-intensity narrative, (3) the size of guidance raises, (4) capital-return signaling. Pure in-line prints barely move it.
Phase C — Judge people & books
Lens 9 · Management
- CEO Rick Wallace — CEO since January 2006 (~20 years), ~30+ years at KLA across multiple roles. One of the longest-tenured CEOs in semis; he has run KLA through multiple cycles and the entire ascent to process-control dominance.
- CFO Brent Higgins — presented the Q3 FY2026 financials; quantified the DRAM/tariff margin headwinds candidly. (Note: some legacy sources name Bren Higgins; treat as the same incumbent CFO — exact spelling/tenure n/a precisely.)
- Track record (quantified): under Wallace, FY2025 revenue $12.156B (+~24% YoY by one framing) and net income $4.062B (+47% YoY), FCF margin ~30.8%; cumulative TSR to $489 vs. peer-index $278 on a $100 base. Process-control share climbed to ~58% and metrology/inspection share to ~74% on his watch.
- Capital allocation — exemplary. 17th consecutive annual dividend increase; 21% dividend hike to $2.30/qtr (pre-split); repurchase authorization expanded by $7B (toward ~$11–20B cumulative authority across sources); a completed multi-year buyback retired ~13.7% of shares (~19.3M, ~$9.69B). Target: >90% of FCF returned. This is a disciplined compounder's capital-return profile, funded by real FCF, not debt.
- Skin in the game: insider ownership is low (~0.09%, ~$212M; insiders <2% collectively) — typical for a long-public mega-cap; Wallace held ~71,383 shares after a planned (10b5-1) sale. Routine programmatic selling, not a red flag — but alignment is via comp/equity awards, not founder-scale ownership.
- Archetype: seasoned professional manager / operator-steward, not founder. For a moat-defense business at scale, that is the right archetype — the job is disciplined R&D reinvestment + capital return, which he has executed.
- Red flags: none material surfaced (no related-party deals, no promotional behavior, no strategy thrash). The split + dividend + buyback cadence reads as confident, not desperate.
Lens 10 · Forensic Red Flags
Web-only; balance-sheet line detail (receivables/inventory/DSO/DIO trends, SBC as % of non-GAAP) is n/a without the filings. Upgrade on ingest-filing.ts.
- Non-GAAP vs GAAP gap: KLA guides and reports prominently on non-GAAP (e.g., 62.2% GM, $9.40 EPS). Standard for the group, but the GAAP bridge (SBC, amortization of acquired intangibles from the Orbotech deal, restructuring) should be checked — flag for filing review. SBC magnitude
n/a.
- Inventory/receivables vs revenue: in a supply-constrained up-cycle ("as fast as we can go"), inventory builds can be demand-pull (good) or channel-stuff (bad). Given the order-backlog narrative and capacity-gated framing, the benign read is more likely — but the receivables/inventory-vs-revenue check is exactly the forensic step the filings are needed for. Not verifiable web-only.
- Goodwill/intangibles: KLA carries goodwill/intangibles from the 2019 Orbotech acquisition (PCB & Component Inspection + Specialty segments). No impairment flagged in sources; carrying value/impairment-test detail
n/a.
- Cash flow vs earnings: FCF margin ~30.8% and >90%-of-FCF return target imply earnings are converting to cash (a strong anti-red-flag signal). Precise CFO-vs-NI reconciliation
n/a.
- Margin "headwind" disclosure: management volunteered and quantified DRAM (~100bps) and tariff (50–100bps) GM headwinds rather than letting them surprise — a transparency positive, not a manipulation flag.
Regulatory findings:
- SEC Litigation Releases: None naming KLA Corporation, 2021-06-17 → 2026-06-17 (EDGAR EFTS, LR).
- SEC AAERs: None found (note: the AAER EFTS query returned an HTTP 500 server error this run, so treat AAER as "no finding, but not fully confirmed" — re-run on next pass).
- Non-SEC enforcement (FTC/DOJ/FDA/etc.): no material enforcement actions surfaced in the Lens-5/8 web sweeps. Export-control compliance is an operating constraint (BIS rules), not an enforcement action against KLA — KLA has been complying (halting advanced sales to China), not penalized. A targeted
"KLA Corporation" (DOJ OR BIS OR settlement OR penalty) enforcement search is n/a — not separately run this pass; flag for refresh.
- 10-K Item 3 (Legal Proceedings):
n/a (SEC fetch 403; ingest the 10-K to quote directly).
- Net: no material regulatory/legal findings via SEC EDGAR EFTS-LR and the web sweep as of 2026-06-17; AAER and 10-K Item 3 not fully confirmed this run (EFTS 500 + EDGAR 403) — close these on the next ingest pass.
Phase D — Project & stress-test
Lens 11 · Forward Projection (FY2026E → FY2028E EPS)
Per --watchlist rules, no forecast.ts create logged (breadth loop). All outputs `` with arithmetic; inputs labeled. KLA fiscal year ends June 30. EPS below is post-split-adjusted (÷10 from the pre-split figures management guides).
Anchors (pre-split → post-split):
- FY2025 actual revenue $12.16B.
- Q1–Q3 FY2026 + Q4 guide: Q3 rev $3.415B, Q4 guide $3.575B; FY2026 guided high-teens % growth → ~$14.2–14.4B.
- Q4 FY2026 non-GAAP EPS guide $9.87 pre-split = ~$0.99 post-split; implied FY2026 non-GAAP EPS ~$37–38 pre-split ≈ ~$3.7–3.8 post-split.
Base / Bull / Bear (post-split non-GAAP EPS):
| Path | FY2026E | FY2027E | FY2028E | Key assumptions |
|---|
| Base | ~$3.75 | ~$4.50 | ~$5.20 | FY26 high-teens growth (guided); FY27 +~18% rev on continued AI/packaging + process-control intensity rising toward 9%, DRAM/tariff headwinds fade (+~50bps GM recovery); FY28 +~13% rev decelerating to trend, buyback −1.5%/yr share count. EPS grows faster than revenue via op-leverage + buyback. |
| Bull | ~$3.85 | ~$5.00 | ~$6.10 | WFE stays "as fast as we can go" through CY2027; advanced packaging >$1.5B; intensity hits 9% early; GM back to ~63%+; aggressive buyback. Tracks toward the 2030 model (see below). |
| Bear | ~$3.65 | ~$3.80 | ~$3.70 | A WFE air-pocket / digestion year in CY2027 (post-AI-capex normalization) + a sharper China step-down (controls tighten) → revenue flat-to-down a year; GM −150bps on mix; buyback cushions EPS but can't fully offset. |
Management's own 2030 model (the bull North Star): revenue $26B ±$2.5B, non-GAAP EPS $84 (= ~$8.40 post-split), operating margin 45–47%, on 9% process-control intensity / $215B WFE. To hit ~$8.40 post-split EPS by CY2030 from ~$3.75 in FY2026 implies a ~17% EPS CAGR — aggressive but internally consistent with the intensity + service + buyback levers.
Brier forecast (NOT logged this pass): the natural tracked claim would be "KLAC FY2027 non-GAAP EPS ≥ $4.40 (post-split), p≈0.62, resolves 2027-07-31." Recorded here for the next /thesis/forecast pass; not created in the watchlist loop.
Lens 12 · Bull vs Bear
Bull case. KLA is the rare semi-cap business that compounds through the cycle because its revenue is levered to complexity, not units — and complexity only goes up (sub-2nm, 3D DRAM, chiplets, HBM4, advanced packaging). It owns ~58% of process control and >85% of optical inspection with a data flywheel and requalification moat no challenger can scale into. The AI build-out is additive on two axes: more leading-edge wafers and more inspection steps per wafer. Advanced packaging (#1 position, $635M→$1B, +70%) is a brand-new growth leg. Management is a disciplined, 20-year operator returning >90% of FCF. The 2030 model ($26B rev, ~$8.40 post-split EPS, 45–47% op margin) is ambitious but built on a credible intensity ramp (7.4%→9%). At ~35× forward — cheaper than ASML, in line with Lam — you are not overpaying for the highest-quality moat in the group.
Bear case (permanent-impairment risks).
- China localization is a slow structural leak, not a one-time hit. Export controls have forced China to build domestic process-control capacity; today KLA's largest Chinese rival is <1% of China's market, but Naura/AMEC are gaining in adjacent WFE. China was 41%→30%→~26% (quarterly) and falling. If China rebuilds an indigenous inspection ecosystem over 5–10 years, KLA permanently loses a quarter of its TAM. This is the only risk that is genuinely structural.
- WFE cyclicality is not repealed — it's dampened. A post-AI-capex digestion year would compress revenue and de-rate a stock priced for secular compounding. "As fast as we can go" is a cycle-peak statement.
- Valuation is the live risk. Trailing P/E ~72, EV/EBITDA ~34. The forward multiple only looks reasonable if high-teens growth lands. Any guidance wobble re-rates a richly-owned, heavily-run name fast.
Pre-mortem (18 months out, thesis broke): Most likely cause — a 2027 WFE digestion air-pocket coincides with a tightening of China controls (or Chinese retaliation/localization milestone), guidance is cut from "high-teens" to "flat," and a stock that had run +195% in a year gives back 30–40% as the secular-compounder narrative is questioned. Secondary cause — DRAM-cost/tariff headwinds prove stickier than "through CY2026," pinning GM below 62% and breaking the op-leverage story.
Are multiples too high? On trailing yes; on forward fair-for-quality conditional on the growth landing. This is an expectations risk, not a quality risk.
Contrarian view (what the market refuses to see): The consensus frames China as KLA's big risk. The subtler, under-appreciated point is the opposite: process-control intensity rising from 7.4%→9% means KLA's content-per-fab-dollar grows even in a flat WFE year — so the "cyclical equipment" mental model under-rates how much KLA has structurally de-cyclicalized itself. The market still prices KLA partly as a cyclical; it increasingly behaves like a complexity-toll annuity.
Lens 13 · Devil's Advocate (short-seller)
Dismantling the bull case:
- Where revenue is concentrated → the kill shot. Revenue is concentrated in (a) a handful of leading-edge fabs (TSMC/Samsung/Intel/SK Hynix/Micron) and (b) geographically in Taiwan + China. A Taiwan disruption (the entire leading-edge ecosystem's single point of failure) would hit KLA harder than almost any name — it sells the picks for the one geography that matters most.
- The moat is weaker in mature/trailing-edge China than bulls admit. China's domestic fabs buying domestic inspection tools don't need KLA's leading-edge sensitivity. Export controls gifted Chinese OEMs a protected home market to climb the learning curve — exactly how SMIC/Naura/AMEC got started in their categories. The <1% share today is the beginning of a localization curve, not proof it can't happen.
- Most dangerous competitor bulls underestimate: not Applied Materials (losing share) — it's the Chinese national champion(s) (Naura/AMEC + an inspection-focused entrant) over a 7–10 year horizon, subsidized and shielded. In the leading edge, watch Applied Materials' eBeam + Onto Innovation for niche encroachment, and ASML's computational-litho/metrology adjacency.
- Capital-allocation nitpicks: none egregious — but buying back stock at ~70× trailing while the stock is up 195% is buying high; if a digestion year hits, that buyback will look ill-timed. Insider ownership is negligible (~0.09%), so management's downside alignment is via comp, not co-investment.
- What must hold for today's price: high-teens revenue growth in FY2026 and continued double-digit growth into FY2027–28; process-control intensity actually climbing to ~9%; China not collapsing faster than the rest grows; GM staying ~62%+.
- If growth disappoints 20–30%: a forward multiple of ~35× on EPS that comes in 25% light = the stock is suddenly ~47× on the lower number → a 30–40% drawdown is easily justified. The valuation has no margin of safety for a growth miss.
- Single permanent-impairment scenario + plausibility: China builds a credible indigenous process-control supplier and KLA loses ~25% of TAM by ~2032. Plausibility: low-to-moderate over 3 years, moderate over 7–10 — inspection is the hardest WFE category to replicate (optics + algorithms + data flywheel), so this is a slow bleed, not a cliff. The faster, lower-probability cliff is a Taiwan event.
Lens 14 · Management Questions (15, ordered by information value)
- China is ~26% of quarterly revenue and falling — what is your floor assumption for China, and how much of the lost China TAM do you assume migrates permanently to domestic Chinese suppliers vs. is recoverable?
- Your 2030 model assumes process-control intensity rises from 7.4% to 9% — what specifically drives the last ~160bps, and what would cause it to stall at ~8%?
- "WFE is as fast as we can go as an industry" — when this capacity constraint eases (2027–28), does KLA's growth decelerate to WFE growth, or does intensity keep you above it?
- How replicable is your optical-inspection moat by a subsidized, protected Chinese entrant over a 7–10 year horizon — what is the single hardest thing for them to copy?
- Advanced packaging is
$635M→$1B (+70%) — what is the steady-state TAM and your share ceiling there, and how does the competitive set differ from front-end inspection?
- DRAM-cost and tariff headwinds are ~150–200bps combined "through CY2026" — what is the gross-margin trajectory into FY2027 once they roll off, and is 63%+ structural?
- You target >90% of FCF returned — at ~70× trailing earnings, how do you think about buyback value vs. simply offsetting dilution? Would you slow buybacks at these multiples?
- Where is your installed-base service annuity most at risk — tool retirements, China service restrictions, or customers in-housing analytics?
- What is the realistic second-source risk: which customers are actively qualifying a competitor's inspection/metrology tool today, and in which segments?
- How exposed is the leading-edge franchise to a single-geography (Taiwan) disruption, and what is your operational hedge?
- Memory (HBM/3D-DRAM) is ~18% of process-control systems — how high can that mix go as HBM4/16-Hi ramps, and is memory process-control intensity now truly at logic parity?
- Capital intensity of your own R&D: what % of revenue must stay in process-control R&D to hold ~58% share, and where is the diminishing-returns line?
- Orbotech (PCB/Specialty) has been a smaller grower — is it core, or a candidate for divestiture to refocus on process control?
- What would have to be true for you to make another large acquisition, and what is off-limits on antitrust grounds given your share?
- Succession: Rick has led for ~20 years — what is the bench and the transition plan, and how do you protect the culture/roadmap through a CEO change?